CTOs on the Move

Sirnaomics

www.sirnaomics.com

 
Sirnaomics, Inc. is a biopharmaceutical company discovering and developing novel targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sirnaomics.com
  • 401 Professional Drive Suite 280
    Gaithersburg, MD USA 20879
  • Phone: 301.740.1730

Executives

Name Title Contact Details
Dmitry Samarsky
Chief Technology Officer Profile

Funding

Sirnaomics raised $25M on 06/05/2018
Sirnaomics raised $11M on 01/11/2019
Sirnaomics raised $22M on 04/29/2019
Sirnaomics raised $105M on 10/23/2020
Sirnaomics raised $105M on 07/01/2021

Similar Companies

SST Corporation

SST Corporation is a Clifton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Viking Therapeutics

Novel therapeutics for metabolic and endocrine disorders

Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.

Families First Pediatrics

With locations in South Jordan & Riverton Utah, our experienced pediatricians & caring team of professionals provides comprehensive care for your children.

BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.